Skip to Main Content

An official website of the United States government

Modifiable risk factors for benign prostatic hyperplasia

Principal Investigator
Name
Siobhan Sutcliffe
Institution
Washington University
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2009-0167
Initial CDAS Request Approval
Nov 4, 2009
Title
Modifiable risk factors for benign prostatic hyperplasia
Summary
Benign prostatic hyperplasia (BPH) is a common benign condition of the prostate associated with the development of lower urinary tract symptoms (LUTS). This condition is highly prevalent and the incidence increases with age. Epidemiologic studies have examined a wide range of factors that may be associated with the development of BPH. However, to date, factors clearly associated with BPH development have not yet been identified. The current proposal seeks to study several potential risk factors to determine their association with incident BPH. Previous studies in the PLCO cohort have examined prevalent BPH, but to date none have examined incident BPH; this is true for many other cohort studies. The current study proposes to examine whether histories of self-reported sexually transmitted infections (STIs), such as gonorrhea and syphilis, young-onset prostatitis, and serologically detected STIs (Chlamydia trachomatis, human papillomavirus (HPV) types 16 and 18, herpes simplex virus (HSV) type 2, cytomegalovirus (CMV), and human herpesvirus (HHV) type 8) are associated with prevalent BPH among participants in the PLCO trial. It will also determine whether histories of these STIs are associated with incident BPH. Finally, the study proposes to assess other more commonly studied possible risk factors for BPH, such as use of aspirin and ibuprofen, smoking, obesity and physical activity level, and alcohol consumption in relation to incidence of BPH during PLCO follow-up. We have selected to study these risk factors for the development of incident BPH because they have been previously associated with prevalent BPH in the PLCO and other cohorts. Additionally, these factors are each potentially modifiable risk factors, such that if they are found to be associated with incident BPH in a relatively short time frame, such as the proposed follow-up period here, future studies could be directed at the effect of lifestyle modification on the incidence and effects of BPH.
Aims

The specific aims of the study are: 1) To determine whether histories of STIs are associated with prevalent and incident BPH among men in the PLCO trial. a) To determine whether histories of self-reported STIs (gonorrhea and syphilis) and young-onset prostatitis are associated with prevalent BPH. b) To determine whether histories of serologically detected STIs (Chlamydia trachomatis, HPV-16, HPV-18, HSV-2, CMV and HHV-8) are associated with prevalent BPH among participants from the PLCO nested case-control study of STIs and prostate cancer. c) To determine whether histories of self-reported STIs (gonorrhea and syphilis) and young-onset prostatitis are associated with incident BPH. 2) To determine whether regular aspirin and ibuprofen use in the year before baseline are associated with incident BPH among men in the PLCO trial. 3) To determine whether cigarette, cigar or pipe smoking before baseline are associated with incident BPH among men in the PLCO trial. 4) To determine whether BMI at ages 20, 50 and baseline are associated with incident BPH among men in the PLCO trial. 5) To determine whether current physical activity levels and physical activity levels at age 40 are associated with incident BPH among men in the PLCO trial. 6) To determine whether alcohol consumption is associated with incident BPH among men in the PLCO trial. 7) To determine whether diabetes and hypertension are associated with incident BPH among men in the PLCO trial.

Collaborators

Gerald Andriole (Washington University)
Robert Grubb (Washington University)
Ann Hsing (DCEG)

Related Publications